SARS CoV 2 Infection: Clinical Trials

17 trials for SARS CoV 2 Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 3 unknown, 2 recruiting, 1 withdrawn. 17 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Completed 11, Unknown 3, Recruiting 2, Withdrawn 1
Phase 34Completed 3, Unknown 1
Phase 12Completed 2

Follow SARS CoV 2 Infection: new trials by email Literature Review of SARS CoV 2 Infection trials Research Report on SARS CoV 2 Infection

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment - Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS)
Phase 2RecruitingVanderbilt University Medical Center502025-12-182026-01-22
Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
Remdesivir (RDV) - COVID - 19, Renal Transplant
Phase 2RecruitingFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia152025-09-012025-09-29
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
IMNN-101 - SARS CoV 2 Infection
Phase 1 / Phase 2CompletedImunon242024-06-042025-07-23
Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women
TURKOVAC - COVID-19, SARS CoV 2 Infection
Phase 2WithdrawnHealth Institutes of Turkey2024-01-012025-05-30
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
BIMERVAX, SIIV - SARS CoV 2 Infection, Influenza, Human
Phase 2CompletedHipra Scientific, S.L.U2792023-09-042026-11-17
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
Prolectin-M - COVID-19, SARS CoV 2 Infection
Phase 2UnknownBioxytran Inc.402023-09-012023-09-28
Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
BIMERVAX - SARS CoV 2 Infection
Phase 2CompletedHipra Scientific, S.L.U2422023-06-082026-11-17
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo - COVID-19 Pandemic, Immunogenicity
Phase 2CompletedSheba Medical Center1792022-09-052024-02-21
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Ad26.COV2.S - COVID-19, Vaccine Reaction
Phase 2UnknownANRS, Emerging Infectious Diseases2002022-06-022024-03-27
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine - COVID -19, SARS CoV 2 Infection
Phase 2CompletedVictoria Biomedical Research Institute19192022-05-182026-02-13
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection
Phase 2 / Phase 3CompletedBelfast Health and Social Care Trust322022-05-162023-09-07
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
PHH-1V - SARS CoV 2 Infection
Phase 2 / Phase 3CompletedHipra Scientific, S.L.U2402022-05-122026-11-17
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
Sotrovimab - SARS CoV 2 Infection
Phase 2CompletedSophia Koo, M.D.932022-02-072024-08-15
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
Recombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo - SARS CoV 2 Infection
Phase 2CompletedLaboratorio Avi-Mex, S.A. de C.V.1582021-11-232025-10-02
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40 - Covid19, SARS CoV 2 Infection
Phase 1 / Phase 2CompletedLaboratorios Hipra, S.A.302021-08-162023-03-01
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
Pfizer/BioNTech (BNT162b2), Moderna - SARS CoV 2 Infection, COVID-19
Phase 2 / Phase 3UnknownDHR Health Institute for Research and Development10002021-07-302022-03-29
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
Raloxifene, Placebo - SARS CoV 2 Infection
Phase 2 / Phase 3CompletedDompé Farmaceutici S.p.A612021-01-222023-12-26

Narrower conditions

COVID-19 (17)  ·  Influenza, Human (1)  ·  Pneumonia (1)  ·  Post-Acute COVID-19 Syndrome (1)  ·  Postural Orthostatic Tachycardia Syndrome (1)

Broader conditions

Coronaviridae Infections (17)  ·  Coronavirus Infections (17)  ·  Infections (17)  ·  Lung Diseases (17)  ·  Nidovirales Infections (17)  ·  Pneumonia, Viral (17)  ·  RNA Virus Infections (17)  ·  Respiratory Tract Diseases (17)  ·  Respiratory Tract Infections (17)  ·  Virus Diseases (17)  ·  Pneumonia (16)  ·  Autonomic Nervous System Diseases (1)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Nervous System Diseases (1)

Interventions

2019-nCoV Vaccine mRNA-1273 (2)  ·  BNT162 Vaccine (2)  ·  Ad26COVS1 (1)  ·  HIPRA COVID-19 vaccine (1)  ·  KPNA1 protein, human (1)  ·  Raloxifene Hydrochloride (1)  ·  Sodium Chloride (1)  ·  TURKOVAC (1)  ·  galactomannan (1)  ·  icatibant (1)  ·  mRNA-1273.214 COVID-19 vaccine (1)  ·  remdesivir (1)  ·  sinovac COVID-19 vaccine (1)  ·  sotrovimab (1)

Sponsors

Hipra Scientific, S.L.U (3)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Belfast Health and Social Care Trust (1)  ·  Bioxytran Inc. (1)  ·  DHR Health Institute for Research and Development (1)  ·  Dompé Farmaceutici S.p.A (1)  ·  Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)  ·  Health Institutes of Turkey (1)  ·  Imunon (1)  ·  Laboratorio Avi-Mex, S.A. de C.V. (1)  ·  Laboratorios Hipra, S.A. (1)  ·  Sheba Medical Center (1)  ·  Sophia Koo, M.D. (1)  ·  Vanderbilt University Medical Center (1)  ·  Victoria Biomedical Research Institute (1)

Countries

Spain (6)  ·  United States (4)  ·  Turkey (Türkiye) (2)  ·  France (1)  ·  Israel (1)  ·  Italy (1)  ·  Kenya (1)  ·  Mali (1)  ·  Mexico (1)  ·  United Kingdom (1)

Top investigators

Teresa Prat (3)  ·  Cyndya Shibao, M.D (1)  ·  Douglas Faller, MD (1)  ·  Elia Torroella (1)  ·  Francesco Sergio, MD, PhD (1)  ·  Gili Regev-Yochay, MD (1)  ·  Jennifer Manne-Goehler, MD, ScD (1)  ·  Joe Kidney, MD (1)  ·  Laura Castro, MD (1)  ·  Niels Hansen, MD (1)  ·  Odile Launay (1)  ·  Samba Sow (1)  ·  Sarah P Hammond, MD (1)  ·  Sohail Rao, MD,MA,DPhil (1)  ·  Sophia Koo, MD (1)

Results publications

PMID 35582123, PMID 36435633, PMID 37328890, PMID 37775521, PMID 38035747, PMID 38806352, PMID 39527880